A phase I first-in-human study of PRTH-101, an IgG1 monoclonal antibody targeting DDR1, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies

被引：0

作者：

Sen, S. ^{[1
]}

Spira, A. I. ^{[2
]}

Sommerhalder, D. ^{[3
]}

Meric-Bernstam, F. ^{[4
]}

Subbiah, V. ^{[4
]}

Berlin, J. D. ^{[5
]}

Parikh, A. ^{[6
]}

Cecchini, M. ^{[7
]}

Sanborn, R. E. ^{[8
]}

Chablani, P. V. ^{[9
]}

Peoples, G. E. ^{[10
]}

Schurpf, T. ^{[11
]}

Dillon, L. A. ^{[12
]}

Clifton, G. T. ^{[13
]}

Eder, J. P. ^{[14
]}

Tolcher, A. W. ^{[15
]}

机构：

[1] NEXT Oncol TM, Phase 1 Trial Ctr, San Antonio, TX USA

[2] Virginia Canc Specialist, Res Inst, Fairfax, VA USA

[3] NEXT Oncol TM, Oncol, San Antonio, TX USA

[4] Univ Texas MD Anderson Canc Ctr, Invest Canc Therapeut Dept, Houston, TX USA

[5] Vanderbilt Univ, Dept Med, Med Ctr, Preston Canc Res Bldg, Nashville, TN USA

[6] MGH Massachusetts Gen Hosp, Dept Gastrointestinal Oncol, Boston, MA USA

[7] Yale Univ, Yale Canc Ctr, Oncol, Sch Med, New Haven, CT USA

[8] Earle A Chiles Res Inst, Robert Franz Canc Ctr, Med Oncol, Portland, OR USA

[9] UPMC Hillman Canc Ctr, Med Oncol, Pittsburgh, PA USA

[10] Lumabridge LLC, Dept Surg, San Antonio, TX USA

[11] Parthenon Therapeut, Prot Sci, Cambridge, MA USA

[12] Parthenon Therapeut, Translat Med, Cambridge, MA USA

[13] Parthenon Therapeut, Clin Sci, Boston, MA USA

[14] Parthenon Therapeut, Clin Dev, Boston, MA USA

[15] NEXT Oncol TM, Clin Res Director, San Antonio, TX USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2976

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1079TiP

引用

页码：S649 / S650

页数：2

共 50 条

[21] A phase 1/1b first-in-human (FIH) study of JZP898 as monotherapy and in combination with pembrolizumab in adult patients with advanced or metastatic solid tumors.
McKean, Meredith
Hutson, Thomas E.
Piha-Paul, Sarina A.
Micaily, Ida
Liao, Mingxiang
Humphreys, Robin
Brock, Graham
Sahr, Natasha
Amber, Vian
Spira, Alexander I.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[22] First-in-human phase 1b study of ATRC-101, a patient-derived antibody with a tumor-specific target, as monotherapy or in combination with pembrolizumab, in patients with solid tumors.
Benjamin, Jonathan E.
Higgins, Nicholas
Millward, Carl
DeFalco, Jeff
Manning-Bog, Amy
Aydin, Iraz T.
Zhang, Danhui
Lippow, Shaun M.
Scholz, Alexander
Leung, Yvonne
Zhu, Yanhong
Sedello, Anna
Rogers, Zane
Dhawan, Ish K.
Emerling, Daniel
Robinson, William H.
Serafini, Tito A.
Greenberg, Norman M.
CANCER RESEARCH, 2021, 81 (13)
[23] First-in-human phase 1 study of MK-1248, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody, as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors.
Geva, Ravit
Voskoboynik, Mark
Beebe, Amy M.
Gwo, Jennifer
Dobrenkov, Konstantin
Chartash, Elliot
Long, Georgina V.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[24] FIRST-IN-HUMAN RESULTS WITH THE NOVEL TUMOR-TARGETING ANTIBODY ATRC-101: PHASE 1B STUDY IN PATIENTS WITH SOLID TUMORS
Powderly, John
Jones, Jeremy
Bekaii-Saab, Tanios
Xing, Yan
Weroha, S. John
Ulahannan, Susanna
Doroshow, Deborah
Valdes-Albini, Frances
Millward, Carl
Walter, Kimberly
Wrong, Andrew
Del Castillo, Paul
Wang, Lixia
Ngan Nguyen
Whidden, Mark
Benjamin, Jonathan
Isakoff, Steven
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A548 - A548
[25] First-in-human phase I of anti-VISTA monoclonal antibody W0180 with and without anti-PD-1 pembrolizumab in patients with locally advanced or metastatic solid tumors
Gomez-Roca, Carlos
Champiat, Stephane
Cassier, Philippe
Jegou, David
Primard, Marie
Petain, Aurelie
Gueguen-Dorbes, Genevieve
Fabre, Claire
Melero, Ignacio
Marabelle, Aurelien
CANCER RESEARCH, 2024, 84 (07)
[26] A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors
Naing, Aung
Gelderblom, Hans
Gainor, Justin F.
Forde, Patrick M.
Butler, Marcus
Lin, Chia-Chi
Sharma, Sunil
de Olza, Maria Ochoa
Schellens, Jan H. M.
Soria, Jean-Charles
Taylor, Matthew H.
Silva, Antonio P.
Li, Zhonggai
Bilic, Sanela
Cameron, Scott
Infante, Jeffrey R.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[27] First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer
Niu, J.
Maurice-Dror, C.
Lee, D. H.
Kim, D. -W.
Nagrial, A.
Voskoboynik, M.
Chung, H. C.
Mileham, K.
Vaishampayan, U.
Rasco, D.
Golan, T.
Bauer, T. M.
Jimeno, A.
Chung, V.
Chartash, E.
Lala, M.
Chen, Q.
Healy, J. A.
Ahn, M. -J.
ANNALS OF ONCOLOGY, 2022, 33 (02) : 169 - 180
[28] Phase I study of ramucirumab, a recombinant human IgG1 monoclonal antibody inhibiting vascular endothelial growth factor receptor-2, in Chinese patients with advanced solid tumors
Li, Jin
Cao, Junning
Wang, Jin
Li, Baoyue
Chi, Haidong
Gao, Ling
CANCER RESEARCH, 2016, 76
[29] Interim results of the ongoing phase 1-2 clinical trial of KVA12123, an engineered IgG1 targeting VISTA, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors
Yu, Evan Y.
Henry, Jason
Patel, Manish R.
Swiecicki, Paul
Micaily, Ida
Garmezy, Benjamin
Banda, Kalyan
Hayreh, Vinny
Lustig, Kurt
Ovechkina, Yulia
Iadonato, Shawn P.
Guillaudeux, Thierry
Rosen, Lee
CANCER RESEARCH, 2024, 84 (07)
[30] A phase I, first-in-human study of argx-111, a monoclonal antibody targeting c-met in patients with solid tumors.
Aftimos, Philippe G.
Barthelemy, Philippe
Rolfo, Christian D.
Hanssens, Valerie
De Jonge, Natalie
Silence, Karen
Dreier, Torsten
de Haard, Hans
Peeters, Marc
Thibault, Alain
Awada, Ahmad
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

← 1 2 3 4 5 →